PT1025121E - Péptidos capazes de inibir a interacção entre as presenilinas e o péptido beta-amilóide ou o seu precursor - Google Patents

Péptidos capazes de inibir a interacção entre as presenilinas e o péptido beta-amilóide ou o seu precursor Download PDF

Info

Publication number
PT1025121E
PT1025121E PT98951547T PT98951547T PT1025121E PT 1025121 E PT1025121 E PT 1025121E PT 98951547 T PT98951547 T PT 98951547T PT 98951547 T PT98951547 T PT 98951547T PT 1025121 E PT1025121 E PT 1025121E
Authority
PT
Portugal
Prior art keywords
interaction
app
peptide
glu
presenilin
Prior art date
Application number
PT98951547T
Other languages
English (en)
Portuguese (pt)
Inventor
Luc Mercken
Laurent Pradier
Christian Czech
Soline Reboul-Becquart
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT1025121E publication Critical patent/PT1025121E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
PT98951547T 1997-10-24 1998-10-23 Péptidos capazes de inibir a interacção entre as presenilinas e o péptido beta-amilóide ou o seu precursor PT1025121E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9713384A FR2770217B1 (fr) 1997-10-24 1997-10-24 Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
US9567198P 1998-08-07 1998-08-07

Publications (1)

Publication Number Publication Date
PT1025121E true PT1025121E (pt) 2011-11-04

Family

ID=9512632

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98951547T PT1025121E (pt) 1997-10-24 1998-10-23 Péptidos capazes de inibir a interacção entre as presenilinas e o péptido beta-amilóide ou o seu precursor

Country Status (8)

Country Link
AT (1) ATE521630T1 (pl)
DK (1) DK1025121T3 (pl)
ES (1) ES2372586T3 (pl)
FR (1) FR2770217B1 (pl)
PL (1) PL198079B1 (pl)
PT (1) PT1025121E (pl)
SI (1) SI1025121T1 (pl)
ZA (1) ZA989745B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3510244B2 (ja) * 1991-01-21 2004-03-22 エラン ファーマシューティカルス，インコーポレイテッド アルツハイマー病に関するテストおよびモデル
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor

Also Published As

Publication number Publication date
ATE521630T1 (de) 2011-09-15
SI1025121T1 (sl) 2011-12-30
PL198079B1 (pl) 2008-05-30
FR2770217B1 (fr) 2001-12-07
DK1025121T3 (da) 2011-11-28
ES2372586T3 (es) 2012-01-24
FR2770217A1 (fr) 1999-04-30
ZA989745B (en) 1999-05-04
PL340054A1 (en) 2001-01-15

Similar Documents

Publication Publication Date Title
Thinakaran et al. Stable association of presenilin derivatives and absence of presenilin interactions with APP
ES2230551T3 (es) Procedimientos para ayudar al diagnostico de la enfermedad de alzheimer mediante la medicion del peptido (x- 41)amiloide beta y de la proteina tau.
US9200068B2 (en) Compositions and methods related to tauopathy
TWI613212B (zh) 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
WO1994028412A1 (en) Composition and method for in vivo imaging of amyloid deposits
JPH11514333A (ja) アミロイドの凝集の調節剤
US20060034848A1 (en) Methods and compositions for treating Alzheimer's disease
US20050208050A1 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
US20230279064A1 (en) General amyloid interaction motif (gaim)
Kwon et al. Dab1 binds to Fe65 and diminishes the effect of Fe65 or LRP1 on APP processing
CA2238007A1 (en) Cloning and expression of .beta.app-c100 receptor (c100-r)
AU766522B2 (en) Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor
CA2617104A1 (en) Amyloid beta receptor and uses thereof
US20120040389A1 (en) Method for demonstration of a molecular event in a cell by means of fluorescent marker proteins
US6653088B1 (en) Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
PT1025121E (pt) Péptidos capazes de inibir a interacção entre as presenilinas e o péptido beta-amilóide ou o seu precursor
JP2003532413A (ja) γ−セクレターゼ活性の変調
MXPA00003811A (en) PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE&bgr;-AMYLOID PEPTIDE OR ITS PRECURSOR
WO2003044196A1 (fr) Proteines postsynaptiques
Laughery Cellular localization and assembly of the Na, K-ATPase
Cheng Identification of the molecular interaction between the dihydropyridine receptor beta subunit and the ryanodine receptor in skeletal muscle
Sabo Regulation of amyloid protein precursor processing, trafficking and function by FE65, an APP-binding protein
Alseikhan Characterization of the interactions of calmodulin with the cardiac ryanodine receptor